


Dacarbazine-d6

Cat. No.:	HY-B0078S
CAS No.:	1185241-28-4
Molecular Formula:	C ₆ H ₄ D ₆ N ₆ O
Molecular Weight:	188.22
Target:	Nucleoside Antimetabolite/Analog; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Dacarbazine-d6 (Imidazole Carboxamide-d6) is the deuterium labeled Dacarbazine. Dacarbazine (DTIC-Dome; DTIC) is an antineoplastic agent. It has significant activity against melanomas.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. *J Exp Clin Cancer Res*, 2000. 19(1): p. 21-34.
- [3]. Ramanathan, R.K., et al., Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. *Ann Oncol*, 2001. 12(8): p. 1139-43.
- [4]. Middleton, M.R., et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol*, 2000. 18(1): p. 158-66.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA